Enveric Biosciences Q2 net loss widens
ENVB•ENVB•ENVB•ENVB•Enveric said it aims to complete IND-enabling activities and submit an IND for EB-003 in the second half of 2026.
The company expects to initiate a first-in-human Phase 1 trial for EB-003 after the IND submission.
It said recent FDA guidance and industry investment are supportive of its neuroplastogen strategy.
Enveric said it expanded its intellectual property portfolio and raised $6.5 million through offerings and warrant exercises.
The company secured a new US patent for the EVM301 Series and received a Notice of Allowance for the EVM401 Series.
It raised $5.0 million through a private placement and $1.5 million from warrant exercises in the quarter.
US biotechnology firm Enveric Biosciences said its second-quarter net loss widened year over year.
The company advanced IND-enabling studies for EB-003 and reported new preclinical data.
